Business
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET.\n\n \n \n \n \n \n \n\n \nThe presentations by IDEAYA management and key opinion leaders will showcase scientific insights and clinical development opportunities across IDEAYA's synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, GSK101/IDE705 (Pol Theta Helicase) in Phase 1, and the Werner Helicase program for which an IND submission is planned for 2024. In addition, IDEAYA will highlight its next generation initiatives for MTAP-deletion, that include a wholly-owned program where a development candidate nomination is targeted in 2024 and multiple first-in-class clinical combination opportunities. The IDEAYA Investor R&D Day Webcast agenda will be the following:\nAgenda Topics\nThe Synthetic Lethality Paradigm IDEAYA Vision, Strategy and Pipeline (Yujiro S. Hata, CEO)Computational Drug Discovery Overview of Current Approaches at IDEAYA (Mike White, CSO)IDE161 Clinical Data and Program Updates (Timothy Yap, MD Anderson)Emerging Therapeutic Opportunities for MTAP-deletion IDEAYA's Multiple-Pronged Strategy (Mike White, CSO; Darrin Beaupre, CMO)IDEAYA and GSK Partnership Pol Theta Helicase and Werner Helicase Programs (Ramon Kemp, GSK)Key Opinion Leader Presenters\nTimothy Yap, M.D., Associate Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Institute for Personalized Cancer Therapy, M.D. Anderson Cancer CenterRamon Kemp, Ph.D., Vice President, Head, Oncology EDL, Interim Head, Oncology MDL, GSKInvestor R&D Day Webcast Presentation and Registration Information\nIDEAYA's Investor R&D Day webcast presentation will be available on the company's website, at its Investor Relations portal (https://ir.ideayabio.com/) in advance of the investor webcast presentation at approximately 6:00 am ET.\nRegistration is available at https://ir.ideayabio.com/events or https://lifescievents...